美國Seracare HIV-1血清陽轉盤（HIV-1 SC Pnl P）

廣州健侖生物科技有限公司

SeraCare Life Sciences公司主要在美國、歐洲和亞洲提供促進人類和動物診斷和治療學的探索、開發和生產的產品和服務。其業務分為兩個部分：診斷和生物制藥產品和生物服務。診斷和生物制藥產品部門生產和銷售診斷和控制面板產品，用于測試傳染性疾病的臨床實驗室及員工培訓和能力測試。生物服務部門提供生物銀行、來樣加工和測試服務。

美國SeraCare收購BBI公司，即原BBI血清盤已經改名為SeraCare血清盤。

其產品包括有：傳染病陽性質控品、疾病標準品、細菌陽性質控品、人血清白蛋白、人伽馬球蛋白、牛血清白蛋白、血清盤、人血漿、人血清。

SeraCare的血清盤包括：HIV-1轉化盤、HIV性能盤、HBV轉化盤、HBV性能盤、HCV轉化盤、HCV性能盤、弓形蟲性能盤、線性盤和質控盤等等。

我司還提供其它進口或國產試劑盒：登革熱、瘧疾、流感、A鏈球菌、合胞病毒、腮病毒、乙腦、寨卡、黃熱病、基孔肯雅熱、克錐蟲病、違禁品濫用、肺炎球菌、軍團菌、化妝品檢測、食品安全檢測等試劑盒以及日本生研細菌分型診斷血清、德國SiFin診斷血清、丹麥SSI診斷血清等產品。

歡迎咨詢

歡迎咨詢2042552662

美國Seracare HIV-1血清陽轉盤（HIV-1 SC Pnl P）

美國Seracare 

想了解更多的產品及服務請掃描下方二維碼：

【公司名稱】 廣州健侖生物科技有限公司

【市 場 部】    楊永漢

【】 

【騰訊Q Q】 2042552662

【公司地址】 廣州清華科技園創新基地番禺石樓鎮創啟路63號二期2幢101-103室

目前，一些已有的癌癥治療方法需要在實驗室制造抗體與癌細胞中的蛋白質結合，使其能夠被患者免疫系統摧毀，這個過程既耗時又昂貴。韋斯教授稱，他們的發現可以極大地促進抗體的生產效率，而且費用會更少。
該技術在其他生物技術領域及食品生產領域也有很大的應用價值。目前，加州大學歐文分校已經為該技術申請了，并將很快投入市場。
近日，生物學期刊the journal of BioLogical chemistry在線發表了來自美國科學家的一項zui近研究成果。研究人員發現機體能量水平能夠通過視黃醇脫氫酶調控全反式維甲酸的生物合成，通過實驗證明了全反式維甲酸與胰島素信號途徑的相互關系。這一研究成果對研究胰島素相關疾病如二型糖尿病等具有一定意義。
全反式維甲酸(atRA)是一種來自視黃醇(維生素A)的自體有效物質，它能夠調節能量平衡減少肥胖。Kristin M. Obrochta等人發現atRA的合成會受到機體能量水平的調節，這種作用主要是通過調節視黃醇脫氫酶(Rdh)的表達實現的。研究人員在給小鼠饑餓再進食6小時后發現，與饑餓16小時的小鼠相比，肝臟和棕色脂肪中Rdh1的表達水平下降了約80%~90%，在肝臟,胰腺和腎臟中Rdh10的表達下降了約45%~63%，同時發現肝臟內atRA的表達水平也下降。口服葡萄糖或腹腔注射胰島素都會導致肝臟內Rdh1和Rdh10表達下降50%。
研究人員通過體外細胞培養發現，移除培養基中的血清，會增加Rdh10和Rdh16(小鼠Rdh1的同源蛋白)表達，但進行胰島素刺激后，Rdh10和Rdh16的表達水平又發生下降。通過對機制探討發現能量水平可以通過胰島素和Foxo1調節Rdh表達以及atRA的生物合成。

At present, some existing cancer treatment methods require that the antibodies in the laboratory be combined with the proteins in the cancer cells so that they can be destroyed by the patient's immune system. This process is time-consuming and expensive. Professor Weiss said that their discovery can greatly promote the efficiency of antibody production, and the cost will be less.
The technology also has great application value in other areas of biotechnology and food production. Currently, the University of California, Irvine, has applied for a patent for this technology and will soon be on the market.
Recently, the journal of Biological chemistry, an international journal of biological sciences, published a recent research result from American scientists. The researchers found that the energy level of the body can modulate the biosynthesis of all-trans retinoic acid through retinol dehydrogenase, and the relationship between all-trans retinoic acid and the insulin signaling pathway was proved through experiments. This research result has certain significance for the study of insulin-related diseases such as type 2 diabetes.
All-trans retinoic acid (atRA) is an autologous substance derived from retinol (vitamin A) that regulates energy balance and reduces obesity. Kristin M. Obrochta et al. found that the synthesis of atRA is regulated by the body's energy level, which is mainly achieved by regulating the expression of retinol dehydrogenase (Rdh). The researchers found that after 6 hours of starvation and feeding of mice, the expression levels of Rdh1 in liver and brown fat were reduced by about 80% to 90% compared to mice that were hungry for 16 hours, Rdh10 in the liver, pancreas and kidneys. The expression decreased by approximay 45% to 63%, and it was also found that the level of atRA in the liver also decreased. Oral glucose or intraperitoneal injections of insulin all cause a 50% decrease in the expression of Rdh1 and Rdh10 in the liver.
Using in vitro cell culture, the researchers found that removing the serum from the culture medium increased the expression of Rdh10 and Rdh16 (a homolog of mouse Rdh1), but after insulin stimulation, the expression levels of Rdh10 and Rdh16 decreased again. By investigating the mechanism for the discovery of energy levels, Rdh expression and atRA biosynthesis can be regulated by insulin and Foxo1.